You are viewing the site in preview mode

Skip to main content

Advertisement

Contact Hyun Cheol Chung

From: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Contact corresponding author